DOCSLIB.ORG

Pulmonary Aspergillosis: a Clinical Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pulmonary Aspergillosis: a Clinical Review Eur Respir Rev 2011; 20: 121, 156–174 DOI: 10.1183/09059180.00001011 CopyrightßERS 2011 REVIEW Pulmonary aspergillosis: a clinical review M. Kousha, R. Tadi and A.O. Soubani ABSTRACT: Aspergillus is a mould which may lead to a variety of infectious, allergic diseases AFFILIATION depending on the host’s immune status or pulmonary structure. Invasive pulmonary aspergillosis Division of Pulmonary Critical Care and Sleep Medicine, Wayne State occurs primarily in patients with severe immunodeficiency. The significance of this infection has University School of Medicine, dramatically increased with growing numbers of patients with impaired immune state associated Detroit, MI, USA. with the management of malignancy, organ transplantation, autoimmune and inflammatory conditions; critically ill patients and those with chronic obstructive pulmonary disease appear to CORRESPONDENCE A.O. Soubani be at an increased risk. The introduction of new noninvasive tests, combined with more effective Division of Pulmonary Critical Care and better-tolerated antifungal agents, has resulted in lower mortality rates associated with this and Sleep Medicine infection. Chronic necrotising aspergillosis is a locally invasive disease described in patients with Wayne State University chronic lung disease or mild immunodeficiency. Aspergilloma is usually found in patients with School of Medicine Harper University Hospital previously formed cavities in the lung, whereas allergic bronchopulmonary aspergillosis, a 3990 John R - 3 Hudson hypersensitivity reaction to Aspergillus antigens, is generally seen in patients with atopy, asthma Detroit or cystic fibrosis. This review provides an update on the evolving epidemiology and risk factors of MI 48201 the major manifestations of Aspergillus lung disease and the clinical manifestations that should USA E-mail: [email protected] prompt the clinician to consider these conditions. Current approaches for the diagnosis and management of these syndromes are discussed. Received: Jan 23 2011 KEYWORDS: Aspergillosis, diagnosis, management, pulmonary, risk factors Accepted after revision: March 10 2011 PROVENANCE spergillus spp. are widespread in the clinical presentations, radiological features, diag- Submitted article, peer reviewed. environment and are commonly isolated nostic criteria, management options and outcome. A from both the outdoor environment (i.e. soil, plant debris) and indoor environment, INVASIVE PULMONARY ASPERGILLOSIS including hospitals. Pulmonary disease is caused IPA was first described in 1953 [3]. Due to mainly by Aspergillus fumigatus and has a widespread use of chemotherapy and immuno- spectrum of clinical syndromes (fig. 1) [1]. suppressive agents, its incidence has increased over the past two decades [4, 5]. Of all autopsies Invasive pulmonary aspergillosis (IPA) is a performed between 1978 and 1992, the rate of severe disease, and can be found not only in invasive mycoses increased from 0.4% to 3.1%, as severely immunocompromised patients, but also documented by GROLL et al. [6]. IPA increased in critically ill patients and those with chronic from 17% to 60% of all mycoses found on autopsy obstructive pulmonary disease (COPD). Chronic over the course of the study. The mortality rate of necrotising aspergillosis (CNA) is locally inva- IPA exceeds 50% in neutropenic patients and sive and is seen mainly in patients with mild reaches 90% in haematopoietic stem-cell trans- immunodeficiency or with a chronic lung dis- plantation (HSCT) recipients [7, 8]. ease. Aspergilloma and allergic bronchopulmon- ary aspergillosis (ABPA) are noninvasive forms Risk factors of Aspergillus lung disease. Aspergilloma is a fungus ball that develops in a pre-existing cavity Alveolar macrophages are the first line of defence within the lung parenchyma, while ABPA is a against inhaled Aspergillus conidia. In the lungs, hypersensitivity manifestation in the lungs that pathogen recognition receptors, such as Toll-like almost always affects patients with asthma or receptors, dectin-1 and mannose-binding lectin, cystic fibrosis [2]. identify specific fungal wall components and produce cytokines that stimulate neutrophil rec- This review systematically describes the main ruitment, the main defence mechanism against European Respiratory Review clinical syndromes associated with pulmonary Aspergillus hyphae [9]. The major risk factor Print ISSN 0905-9180 aspergillosis, covering their incidence, risk factors, for IPA is immunodeficiency (table 1), which Online ISSN 1600-0617 156 VOLUME 20 NUMBER 121 EUROPEAN RESPIRATORY REVIEW M. KOUSHA ET AL. REVIEW: PULMONARY ASPERGILLOSIS Inhalation of Aspergillus spores Chronic lung disease or Asthma Normal Cavitary Immunocompromised mild immunocompromised Cystic fibrosis host lung disease host host Atopy Chronic Invasive Allergic No sequel Aspergilloma necrotising pulmonary bronchopulmonary aspergillosis aspergillosis aspergillosis FIGURE 1. The spectrum of pulmonary aspergillosis. includes neutropenia, HSCT and solid-organ transplantation, the hazard ratio for IPA in the setting of CMV disease increases prolonged therapy with high-dose corticosteroids, haemato- 13.3-fold (95% CI 4.7–37.7) [8]. logical malignancy, cytotoxic therapy, advanced AIDS and Neutrophil dysfunction is another risk factor for IPA and is chronic granulomatous disease (CGD) [1, 10, 15]. seen primarily in CGD. IPA is an important cause of mortality The most important risk factor is neutropenia, especially when in these patients [22]. there is an absolute neutrophil count of ,500 cells?mm-3. The IPA is relatively uncommon in patients with HIV infection, risk of IPA correlates strongly with the duration and degree of especially with the routine use of highly active anti-retroviral neutropenia. The risk in neutropenic patients is estimated to therapy. The incidence of aspergillosis in a large cohort of increase by 1% per day for the first 3 weeks and then by 4% per patients with HIV infection was 3.5 cases per 1,000 person-yrs day thereafter [10]. HSCT and solid-organ transplantation [18]. A low CD4 count (,100 cells?mm-3) is present in almost (especially lung transplantation) are also significant risk factors all cases of AIDS-associated aspergillosis, and half of HIV- [11, 23] Several other factors predispose patients with trans- infected patients with IPA have coexistent neutropenia or are plantation to acquire IPA: multiple immune defects includ- on corticosteroid therapy. The rest of the cases appear to have ing prolonged neutropenia in the pre-engraftment phase of no particular risk factors other than advanced AIDS [19–21]. HSCT; the use of multiple anti-rejection or anti-graft versus There is increased incidence of tracheobronchial involvement host disease (GVHD) therapy (such as corticosteroids and in these patients in addition to the usual clinical picture of IPA cyclosporine); parenteral nutrition; use of multiple antibiotics; [21, 31]. Since isolation of Aspergillus from respiratory secre- and prolonged hospitalisation. tions has poor predictive value for invasive IPA in AIDS There has been a steady increase in the documented cases of patients, a histopathological diagnosis is usually required to IPA following HSCT, where the risk is much higher following establish the diagnosis [32]. Response to therapy in this patient allogeneic rather than autologous HSCT (incidences of 2.3–15% group tends to be particularly poor [19–21, 32, 33]. The and 0.5–4%, respectively) [8, 12–14, 24]. In allogeneic HSCT, the prognosis of HIV-infected patients with IPA is generally poor, highest risk is in patients with severe GVHD (grade III–IV). The with median survival of 3 months following diagnosis [18]. timeline of IPA in these patients follows a bimodal distribution, There are increasing numbers of reports documenting IPA in with a peak in the first month following HSCT, which is immunocompetent patients who do not have the classic risk associated with neutropenia. The second peak is during the factors. Two at-risk groups stand out: patients with severe treatment of GVHD (median 78–112 days post-transplantation) COPD and critically ill patients. IPA is an emerging serious [8, 13, 25]. Currently, the first peak is less significant because of infection in patients with COPD. The majority of these patients the routine use of stem cells instead of bone marrow for have advanced COPD and/or are on corticosteroid therapy. transplantation, nonmyeloablative regimens, the use of colony- Patients with COPD have increased susceptibility to IPA for stimulating factors during neutropenia and the widespread use several reasons, including structural changes in lung architec- of antifungal agents [13, 26]. The second peak has become more ture, prolonged use of corticosteroid therapy [16], frequent significant, especially with the higher incidence of GVHD hospitalisation, broad-spectrum antibiotic treatment, invasive associated with unrelated allogeneic transplantation and treat- procedures, mucosal lesions and impaired mucociliary clear- ment with intensive immunosuppressive therapy, including ance, and comorbid illnesses such as diabetes mellitus, corticosteroids, cyclosporine A, anti-TNF agents, and other alcoholism and malnutrition. It is also possible that abnorm- T-cell depleting strategies [13, 14, 17, 27–29]. alities or deficiencies in surfactant proteins, alveolar macro- phages and Toll-like receptors play a role in the pathogenesis In a study by MARR et al. [14], the probability of IPA reached of IPA in some patients with COPD
Load more

Recommended publications
  • An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies
    Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies This article was published in the following Dove Press journal: Infection and Drug Resistance Aref Shariati 1 Abstract: In patients with hematologic malignancies due to immune system disorders, espe- Alireza Moradabadi2 cially persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality. Zahra Chegini3 Aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis and trichosporonosis are Amin Khoshbayan 4 the most important infections reported in patients with hematologic malignancies that undergo Mojtaba Didehdar2 hematopoietic stem cell transplantation. These infections are caused by opportunistic fungal pathogens that do not cause severe issues in healthy individuals, but in patients with hematologic 1 Department of Microbiology, School of malignancies lead to disseminated infection with different clinical manifestations. Prophylaxis Medicine, Shahid Beheshti University of fi Medical Sciences, Tehran, Iran; and creating a safe environment with proper lters and air pressure for patients to avoid contact 2Department of Medical Parasitology and with the pathogens in the surrounding environment can prevent IFI. Furthermore, due to the Mycology, Arak University of Medical fi For personal use only. absence of speci c symptoms in IFI, rapid and accurate diagnosis reduces
    [Show full text]
  • Fungal Infections from Human and Animal Contact
    Journal of Patient-Centered Research and Reviews Volume 4 Issue 2 Article 4 4-25-2017 Fungal Infections From Human and Animal Contact Dennis J. Baumgardner Follow this and additional works at: https://aurora.org/jpcrr Part of the Bacterial Infections and Mycoses Commons, Infectious Disease Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Baumgardner DJ. Fungal infections from human and animal contact. J Patient Cent Res Rev. 2017;4:78-89. doi: 10.17294/2330-0698.1418 Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience. REVIEW Fungal Infections From Human and Animal Contact Dennis J. Baumgardner, MD Aurora University of Wisconsin Medical Group, Aurora Health Care, Milwaukee, WI; Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI; Center for Urban Population Health, Milwaukee, WI Abstract Fungal infections in humans resulting from human or animal contact are relatively uncommon, but they include a significant proportion of dermatophyte infections. Some of the most commonly encountered diseases of the integument are dermatomycoses. Human or animal contact may be the source of all types of tinea infections, occasional candidal infections, and some other types of superficial or deep fungal infections. This narrative review focuses on the epidemiology, clinical features, diagnosis and treatment of anthropophilic dermatophyte infections primarily found in North America.
    [Show full text]
  • Oral Candidiasis: a Review
    International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Issue 4, 2010 Review Article ORAL CANDIDIASIS: A REVIEW YUVRAJ SINGH DANGI1, MURARI LAL SONI1, KAMTA PRASAD NAMDEO1 Institute of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur (C.G.) – 49500 Email: [email protected] Received: 13 Jun 2010, Revised and Accepted: 16 July 2010 ABSTRACT Candidiasis, a common opportunistic fungal infection of the oral cavity, may be a cause of discomfort in dental patients. The article reviews common clinical types of candidiasis, its diagnosis current treatment modalities with emphasis on the role of prevention of recurrence in the susceptible dental patient. The dental hygienist can play an important role in education of patients to prevent recurrence. The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at‐risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non‐albicans Candida, non‐fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Oral candidiasis is a common fungal infection in patients with an impaired immune system, such as those undergoing chemotherapy for cancer and patients with AIDS. It has a high morbidity amongst the latter group with approximately 85% of patients being infected at some point during the course of their illness. A major predisposing factor in HIV‐infected patients is a decreased CD4 T‐cell count.
    [Show full text]
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • Subcutaneous Phycomycosis: a Review of 31 Cases Seen in Uganda
    27 June 1964 Myelomatosis-Speed et al. BRITISH 1669 Case 10 (19 October 1962); Case 12 (24 February 1964); REFERNCES Case 14 (9 September 1962); and Case 16 (17 February 1963). N. (1947). Lancet, 2, 388. Alwall, Campgn, Case 5 received 10 further courses of melphalan, and the disease Bergel, F., and Stock, J. A. (1953). A.R. Brit. Emp. Cancer Br Med J: first published as 10.1136/bmj.1.5399.1669 on 27 June 1964. Downloaded from 31, 6. remained well controlled until the last 10 weeks of life, when Bergsagel, D. E. (1962). Cancer Chemother. Rep., No. 16, p. 261. the growth extended extremely rapidly. He received one further - Sprague, C. C., Austin, C., and Griffith, K. M. (1962). Ibid., No. 21, p. 87. course of radiotherapy for local pain. Case 9 received eight Bernard, J., Seligmann, M., and Danon, F. (1962). Nouv. Rev. franc. further courses of melphalan, and the disease was well controlled Himat., 2, 611. of ribs which Blokhin, N., Larionov, L., Perevodchikova, N., Chebotareva, L., and except for local pain from pathological fractures Merkulova, N. (1958). Ann. N.Y. Acad. Sci., 68, 1128. was relieved by irradiation. At post-mortem examination a Innes, J. (1963). Proc. roy. Soc. Med., 56, 648. gastric carcinoma, suspected in the last three months of life, - and Rider, W. D. (1955). Blood, 10, 252. Larionov, L. F., Khokhlov, A. S., Shkodinskaja, E. N., Vasina, 0. S., was found. Cases 8, 9, 12, 14, and 16 did not benefit from Troosheikina, V. I., and Novikova, M. A. (1955). Bull.
    [Show full text]
  • COVID-19 Pneumonia: the Great Radiological Mimicker
    Duzgun et al. Insights Imaging (2020) 11:118 https://doi.org/10.1186/s13244-020-00933-z Insights into Imaging EDUCATIONAL REVIEW Open Access COVID-19 pneumonia: the great radiological mimicker Selin Ardali Duzgun* , Gamze Durhan, Figen Basaran Demirkazik, Meltem Gulsun Akpinar and Orhan Macit Ariyurek Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread worldwide since December 2019. Although the reference diagnostic test is a real-time reverse transcription-polymerase chain reaction (RT-PCR), chest-computed tomography (CT) has been frequently used in diagnosis because of the low sensitivity rates of RT-PCR. CT fndings of COVID-19 are well described in the literature and include predominantly peripheral, bilateral ground-glass opacities (GGOs), combination of GGOs with consolida- tions, and/or septal thickening creating a “crazy-paving” pattern. Longitudinal changes of typical CT fndings and less reported fndings (air bronchograms, CT halo sign, and reverse halo sign) may mimic a wide range of lung patholo- gies radiologically. Moreover, accompanying and underlying lung abnormalities may interfere with the CT fndings of COVID-19 pneumonia. The diseases that COVID-19 pneumonia may mimic can be broadly classifed as infectious or non-infectious diseases (pulmonary edema, hemorrhage, neoplasms, organizing pneumonia, pulmonary alveolar proteinosis, sarcoidosis, pulmonary infarction, interstitial lung diseases, and aspiration pneumonia). We summarize the imaging fndings of COVID-19 and the aforementioned lung pathologies that COVID-19 pneumonia may mimic. We also discuss the features that may aid in the diferential diagnosis, as the disease continues to spread and will be one of our main diferential diagnoses some time more.
    [Show full text]
  • Fungal Infection in the Lung
    CHAPTER Fungal Infection in the Lung 52 Udas Chandra Ghosh, Kaushik Hazra INTRODUCTION The following risk factors may predispose to develop Pneumonia is the leading infectious cause of death in fungal infections in the lungs 6 1, 2 developed countries . Though the fungal cause of 1. Acute leukemia or lymphoma during myeloablative pneumonia occupies a minor portion in the immune- chemotherapy competent patients, but it causes a major role in immune- deficient populations. 2. Bone marrow or peripheral blood stem cell transplantation Fungi may colonize body sites without producing disease or they may be a true pathogen, generating a broad variety 3. Solid organ transplantation on immunosuppressive of clinical syndromes. treatment Fungal infections of the lung are less common than 4. Prolonged corticosteroid therapy bacterial and viral infections and very difficult for 5. Acquired immunodeficiency syndrome diagnosis and treatment purposes. Their virulence varies from causing no symptoms to death. Out of more than 1 6. Prolonged neutropenia from various causes lakh species only few fungi cause human infection and 7. Congenital immune deficiency syndromes the most vulnerable organs are skin and lungs3, 4. 8. Postsplenectomy state RISK FACTORS 9. Genetic predisposition Workers or farmers with heavy exposure to bird, bat, or rodent droppings or other animal excreta in endemic EPIDEMIOLOGY OF FUNGAL PNEUMONIA areas are predisposed to any of the endemic fungal The incidences of invasive fungal infections have pneumonias, such as histoplasmosis, in which the increased during recent decades, largely because of the environmental exposure to avian or bat feces encourages increasing size of the population at risk. This population the growth of the organism.
    [Show full text]
  • Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
    Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting a b,c, Alexander Lepak, MD , David Andes, MD * KEYWORDS Invasive candidiasis Pharmacokinetics-pharmacodynamics Therapy Source control Invasive fungal infections (IFI) and fungal sepsis in the intensive care unit (ICU) are increasing and are associated with considerable morbidity and mortality. In this setting, IFI are predominantly caused by Candida species. Currently, candidemia represents the fourth most common health care–associated blood stream infection.1–3 With increasingly immunocompromised patient populations, other fungal species such as Aspergillus species, Pneumocystis jiroveci, Cryptococcus, Zygomycetes, Fusarium species, and Scedosporium species have emerged.4–9 However, this review focuses on invasive candidiasis (IC). Multiple retrospective studies have examined the crude mortality in patients with candidemia and identified rates ranging from 46% to 75%.3 In many instances, this is partly caused by severe underlying comorbidities. Carefully matched, retrospective cohort studies have been undertaken to estimate mortality attributable to candidemia and report rates ranging from 10% to 49%.10–15 Resource use associated with this infection is also significant. Estimates from numerous studies suggest the added hospital cost is as much as $40,000 per case.10–12,16–20 Overall attributable costs are difficult to calculate with precision, but have been estimated to be close to 1 billion dollars in the United States annually.21 a University of Wisconsin, MFCB, Room 5218, 1685 Highland Avenue, Madison, WI 53705-2281, USA b Department of Medicine, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA c Department of Microbiology and Immunology, University of Wisconsin, MFCB, Room 5211, 1685 Highland Avenue, Madison, WI 53705-2281, USA * Corresponding author.
    [Show full text]
  • Candida Auris Fungemia at Tified
    RESEARCH LETTERS This case illustrates the need to better define the geo- Management of Patients with graphic extent and modes of transmission of this debilitat- ing disease so that primary control measures can be iden- Candida auris Fungemia at tified. In addition, health workers must be provided with Community Hospital, the training and tools to diagnose and treat M. ulcerans. Brooklyn, New York, Research into a point-of-care diagnostic test is needed so 1 that timely treatment can minimize disability and costs to USA, 2016–2018 the family. Jenny YeiSol Park,2 Nicole Bradley,3 Acknowledgments Steven Brooks, Sibte Burney, Chanie Wassner Thanks to Emily Duecke, Sidy Ba, Carlos Bleck, and Teunella Wolters for their sharp clinical skills and therapeutic efforts on DOI: https://doi.org/10.3201/eid2503.180927 behalf of this patient. Candida auris is an emerging fungus that can cause inva- sive infections. It is associated with high mortality rates and About the Author resistance to multiple classes of antifungal drugs and is dif- Ms. Turner is a family nurse practitioner living and working in ficult to identify with standard laboratory methods. We de- Dakar, Senegal. Her background includes trauma and pediatric scribe the management and outcomes of 9 patients with C. primary care in high-income and low-income countries. auris fungemia in Brooklyn, New York, USA. References andida auris is an emerging fungus that can cause inva- 1. Sakyi SA, Aboagye SY, Otchere ID, Yeboah-Manu D. Clinical and Csive infections associated with high mortality rates and laboratory diagnosis of Buruli ulcer disease: a systematic review.
    [Show full text]
  • Epidemiology of Invasive Fungal Diseases in Patients With
    Journal of Fungi Article Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach Maria Daniela Bergamasco 1 , Carlos Alberto P. Pereira 1, Celso Arrais-Rodrigues 2, Diogo B. Ferreira 1 , Otavio Baiocchi 2, Fabio Kerbauy 2, Marcio Nucci 3 and Arnaldo Lopes Colombo 1,* 1 Division of Infectious Diseases, Hospital São Paulo-University Hospital, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil; [email protected] (M.D.B.); [email protected] (C.A.P.P.); [email protected] (D.B.F.) 2 Division of Hematology, Hospital São Paulo-University Hospital, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil; [email protected] (C.A.-R.); [email protected] (O.B.); [email protected] (F.K.) 3 Department of Internal Medicine, Hospital Universitário Clementino Frafa Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) Citation: Bergamasco, M.D.; Pereira, are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with mold- C.A.P.; Arrais-Rodrigues, C.; Ferreira, active azoles has been challenged recently because of drug–drug interactions with novel targeted D.B.; Baiocchi, O.; Kerbauy, F.; Nucci, therapies. This is a retrospective, single-center cohort study of consecutive cases of proven or probable M.; Colombo, A.L. Epidemiology of IFD, diagnosed between 2009 and 2019, in adult hematologic patients and HCT recipients managed Invasive Fungal Diseases in Patients with fluconazole prophylaxis and an antifungal diagnostic-driven approach for mold infection.
    [Show full text]
  • Fever, Rash and Fungemia in a Traveler from South China Osamuyimen Igbinosa*, Krishna Dass and Glenn Wortmann
    ical C lin as C e f R o Igbinosa et al., J Clin Case Rep 2015, 5:11 l e a p n o r r DOI: 10.4172/2165-7920.1000639 t u s o J Journal of Clinical Case Reports ISSN: 2165-7920 Case Report Open Access Fever, Rash and Fungemia in a Traveler from South China Osamuyimen Igbinosa*, Krishna Dass and Glenn Wortmann Section of Infectious Diseases, Medstar Washington Hospital Center, Washington DC, USA Abstract Introduction: Penicillium (Talaromyces) marneffei is a dimorphic fungus that is endemic in Southeast Asia and South China, but rarely seen the United States except in immunosuppressed patients who have had travel-related exposure. Case Presentation: A 28 year-old man with advanced HIV/AIDS presented with dyspnea, cough and fever two weeks after returning from Shenzhen, South China. He was treated for presumptive Pneumocystis jiroveci pneumonia with improvement in his symptoms and was then started on antiretroviral therapy. Three weeks later he developed rash and fever, and blood culture grew Penicillium (Talaromyces) marneffei. Conclusion: This case highlights the importance of obtaining a detailed travel history in order to incorporate travel-related diseases in a differential diagnosis. Keywords: HIV/AIDS; Anti-retroviral therapy; Pneumocystis jiroveci A chest x-ray demonstrated bilateral pulmonary infiltrates compatible pneumonia with Pneumocystis jiroveci pneumonia (PJP). Sputum stained for acid-fast bacilli was negative three times, and the patient refused Abbreviations: ART: Antiretroviral Therapy; PJP: Pneumocystis bronchoscopy. He was treated for presumptive PJP with trimethoprim/ jiroveci pneumonia; MALDI- TOF: Matrix-Assisted Laser Desorption/ sulfamethoxazole, with improvement in his dyspnea.
    [Show full text]
  • Clinical and Laboratory Profile of Chronic Pulmonary Aspergillosis
    Original article 109 Clinical and laboratory profile of chronic pulmonary aspergillosis: a retrospective study Ramakrishna Pai Jakribettua, Thomas Georgeb, Soniya Abrahamb, Farhan Fazalc, Shreevidya Kinilad, Manjeshwar Shrinath Baligab Introduction Chronic pulmonary aspergillosis (CPA) is a type differential leukocyte count, and erythrocyte sedimentation of semi-invasive aspergillosis seen mainly in rate. In all the four dead patients, the cause of death was immunocompetent individuals. These are slow, progressive, respiratory failure and all patients were previously treated for and not involved in angio-invasion compared with invasive pulmonary tuberculosis. pulmonary aspergillosis. The predisposing factors being Conclusion When a patient with pre-existing lung disease compromised lung parenchyma owing to chronic obstructive like chronic obstructive pulmonary disease or old tuberculosis pulmonary disease and previous pulmonary tuberculosis. As cavity presents with cough with expectoration, not many studies have been conducted in CPA with respect to breathlessness, and hemoptysis, CPA should be considered clinical and laboratory profile, the study was undertaken to as the first differential diagnosis. examine the profile in our population. Egypt J Bronchol 2019 13:109–113 Patients and methods This was a retrospective study. All © 2019 Egyptian Journal of Bronchology patients older than 18 years, who had evidence of pulmonary Egyptian Journal of Bronchology 2019 13:109–113 fungal infection on chest radiography or computed tomographic scan, from whom the Aspergillus sp. was Keywords: chronic pulmonary aspergillosis, immunocompetent, laboratory isolated from respiratory sample (broncho-alveolar wash, parameters bronchoscopic sample, etc.) and diagnosed with CPA from aDepartment of Microbiology, Father Muller Medical College Hospital, 2008 to 2016, were included in the study.
    [Show full text]